8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Feb 26, 2026·SEC
Material company update
Jan 8, 2026·SEC
Anika Therapeutics, Inc.(ANIK)Earnings, Financials & Key Ratios
ANIK•NASDAQ
Price updated Jun 19, 2026
AboutAnika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.Show more
- Revenue$113M-5.9%
- EBITDA-$5M-276.2%
- Net Income-$11M+80.7%
- EPS (Diluted)-0.76+80.2%
- Gross Margin56.56%-10.8%
- EBITDA Margin-4.72%-287.3%
- Operating Margin-9.8%-130.3%
- Net Margin-9.64%+79.5%
- ROE-7.32%+76.2%
ANIK Key Insights
Anika Therapeutics, Inc. (ANIK) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 83 (top 17%)
- ✓Share count reduced 2.6% through buybacks
- ✓Trading at only 1.4x book value
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when ANIK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
ANIK Price & Volume
Anika Therapeutics, Inc. (ANIK) stock price & volume — 10-year historical chart
Loading chart...
ANIK Growth Metrics
Anika Therapeutics, Inc. (ANIK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years1.95%
5 Years-2.86%
3 Years-0.3%
TTM23.22%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM80.5%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM79.62%
Return on Capital
10 Years4.53%
5 Years-1.31%
3 Years-2.83%
Last Year-6.35%
ANIK Recent Earnings
Anika Therapeutics, Inc. (ANIK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 9/12 qtrs (75%)
Q2 2026Latest
Apr 29, 2026Metric
Actual
Est
EPS
$0.27+485.7%
$0.07
Rev
$30M+5.2%
$28M
Q1 2026
Feb 26, 2026Metric
Actual
Est
EPS
$0.31+348.0%
$0.13
Rev
$31M+6.0%
$29M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.04+100.0%
$0.02
Rev
$28M+0.1%
$28M
Q3 2025
Jul 30, 2025Metric
Actual
Est
EPS
$0.13+0.0%
$0.13
Rev
$28M+2.5%
$28M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.27vs $0.07+485.7% | $30Mvs $28M+5.2% |
| Q1 2026 | Feb 26, 2026 | $0.31vs $0.13+348.0% | $31Mvs $29M+6.0% |
| Q4 2025 | Nov 5, 2025 | $0.04vs $0.02+100.0% | $28Mvs $28M+0.1% |
| Q3 2025 | Jul 30, 2025 | $0.13vs $0.13+0.0% | $28Mvs $28M+2.5% |
Based on last 12 quarters of dataView full earnings history →
ANIK Peer Comparison
Anika Therapeutics, Inc. (ANIK) competitors in Orthopedics, spine, and sports medicine — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MDXG | 545.24M | 3.67 | 11.47 | 19.99% | 7.88% | 12.86% | 0.09 | |
 NVCR | 1.62B | 14.28 | -11.70 | 8.28% | -25.66% | -50.82% | 0.85 | |
 OSUR | 305.85M | 4.25 | -4.52 | -38.1% | -61.93% | -15.09% | 0.04 | |
 ATRC | 1.46B | 28.80 | -120 | 14.88% | -0.83% | -0.95% | 0.18 | |
 LNTH | 6.76B | 103.86 | 30.46 | 0.5% | 18.05% | 24.33% | 0.00 | |
 HALO | 8.13B | 68.55 | 26.78 | 37.55% | 23.13% | 126.27% | 43.89 | |
 ALGN | 13.04B | 182.08 | 32.23 | 0.9% | 10.5% | 10.7% | 0.03 | |
 GMED | 10.69B | 79.23 | 20.21 | 16.65% | 18.92% | 13.04% | 0.03 |
Compare ANIK vs Peers
Anika Therapeutics, Inc. (ANIK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
ANIK Income Statement
Anika Therapeutics, Inc. (ANIK) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 113.42M | 105.56M | 114.61M | 130.46M | 147.79M | 113.83M | 120.79M | 119.91M | 112.82M | 116.26M |
Revenue Growth % | 9.71% | -6.93% | 8.58% | 13.83% | 13.29% | -22.98% | 6.12% | -0.73% | -5.91% | 23.22% |
Cost of Goods Sold | 27.36M | 31.28M | 28.75M | 61.43M | 64.85M | 40.61M | 38.26M | 43.91M | 49.01M | 48.14M |
COGS % of Revenue | 24.13% | 29.63% | 25.08% | 47.09% | 43.88% | 35.67% | 31.67% | 36.62% | 43.44% | - |
Gross Profit | 86.06M▲ 0% | 74.28M▼ 13.7% | 85.86M▲ 15.6% | 69.03M▼ 19.6% | 82.94M▲ 20.2% | 73.22M▼ 11.7% | 82.53M▲ 12.7% | 76M▼ 7.9% | 63.81M▼ 16.0% | 68.12M▲ 0% |
Gross Margin % | 75.87% | 70.37% | 74.92% | 52.91% | 56.12% | 64.33% | 68.33% | 63.38% | 56.56% | 58.59% |
Gross Profit Growth % | 8.45% | -13.69% | 15.6% | -19.61% | 20.16% | -11.72% | 12.72% | -7.92% | -16.04% | - |
Operating Expenses | 40.33M | 52.53M | 51.62M | 97.35M | 80.33M | 69.55M | 81.69M | 81.1M | 74.86M | 80.38M |
OpEx % of Revenue | 35.56% | 49.76% | 45.04% | 74.62% | 54.35% | 61.1% | 67.63% | 67.63% | 66.35% | - |
Selling, General & Admin | 21.54M | 34.34M | 34.95M | 60.06M | 74.1M | 51.23M | 59.92M | 55.55M | 49.09M | 53.95M |
SG&A % of Revenue | 18.99% | 32.53% | 30.49% | 46.04% | 50.13% | 45.01% | 49.61% | 46.33% | 43.51% | - |
Research & Development | 18.79M | 18.19M | 16.66M | 23.43M | 27.33M | 18.32M | 21.76M | 25.54M | 25.77M | 26.42M |
R&D % of Revenue | 16.56% | 17.23% | 14.54% | 17.96% | 18.49% | 16.1% | 18.02% | 21.3% | 22.84% | - |
Other Operating Expenses | 0 | 0 | 0 | 13.85M | -21.09M | 0 | 0 | 0 | 0 | 0 |
Operating Income | 45.73M▲ 0% | 21.75M▼ 52.4% | 34.25M▲ 57.5% | -28.32M▼ 182.7% | 2.62M▲ 109.2% | 3.67M▲ 40.3% | 844K▼ 77.0% | -5.1M▼ 704.4% | -11.05M▼ 116.6% | -12.25M▲ 0% |
Operating Margin % | 40.32% | 20.6% | 29.88% | -21.71% | 1.77% | 3.22% | 0.7% | -4.25% | -9.8% | -10.54% |
Operating Income Growth % | -9.64% | -52.44% | 57.47% | -182.7% | 109.23% | 40.34% | -77% | -704.38% | -116.64% | - |
EBITDA | 50.02M | 27.66M | 40.24M | -14.86M | 16.93M | 18.16M | 15.06M | 3.02M | -5.32M | -6.63M |
EBITDA Margin % | 44.1% | 26.2% | 35.11% | -11.39% | 11.46% | 15.95% | 12.47% | 2.52% | -4.72% | -5.7% |
EBITDA Growth % | -7.95% | -44.7% | 45.48% | -136.92% | 213.96% | 7.23% | -17.05% | -79.95% | -276.23% | -588.58% |
D&A (Non-Cash Add-back) | 4.29M | 5.91M | 5.99M | 13.46M | 14.32M | 14.49M | 14.22M | 8.12M | 5.73M | 5.63M |
EBIT | 45.73M | 21.75M | 34.25M | -14.47M | -18.48M | 3.67M | 844K | -5.1M | -11.05M | -12.25M |
Net Interest Income | 473K | 1.46M | 1.87M | -302K | 0 | 654K | 2.31M | 0 | 0 | 0 |
Interest Income | 473K | 1.46M | 1.87M | 498K | - | 654K | 2.31M | - | 0 | 0 |
Interest Expense | 0 | 0 | 0 | 800K | - | 0 | 0 | - | 0 | 0 |
Other Income/Expense | 473K | 1.46M | 1.87M | -302K | -188K | 654K | 2.31M | 2.34M | 1.74M | 2M |
Pretax Income | 46.2M▲ 0% | 23.21M▼ 49.8% | 36.12M▲ 55.6% | -28.62M▼ 179.2% | 2.43M▲ 108.5% | 4.32M▲ 78.2% | 3.16M▼ 27.0% | -2.76M▼ 187.6% | -9.31M▼ 236.7% | -10.26M▲ 0% |
Pretax Margin % | 40.74% | 21.99% | 31.52% | -21.94% | 1.64% | 3.8% | 2.61% | -2.31% | -8.25% | -8.82% |
Income Tax | 14.39M | 4.49M | 8.93M | -4.64M | -1.71M | 2.12M | 6.59M | 6.06M | 672K | 818K |
Effective Tax Rate % | 31.14% | 19.33% | 24.72% | 16.22% | -70.33% | 49.12% | 208.97% | -219.39% | -7.22% | -7.97% |
Net Income | 31.82M▲ 0% | 18.72M▼ 41.2% | 27.19M▲ 45.2% | -23.98M▼ 188.2% | 4.13M▲ 117.2% | -14.86M▼ 459.4% | -82.67M▼ 456.3% | -56.38M▲ 31.8% | -10.88M▲ 80.7% | -11.06M▲ 0% |
Net Margin % | 28.05% | 17.74% | 23.73% | -18.38% | 2.8% | -13.05% | -68.44% | -47.02% | -9.64% | -9.52% |
Net Income Growth % | -2.25% | -41.16% | 45.25% | -188.19% | 117.24% | -459.43% | -456.34% | 31.79% | 80.7% | 80.5% |
Net Income (Continuing) | 31.82M | 18.72M | 27.19M | -23.98M | 4.13M | 2.2M | -3.44M | -8.83M | -9.98M | -11.08M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | -17.06M | -79.23M | -47.56M | -901K | 523K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | 2.11▲ 0% | 1.27▼ 39.8% | 1.89▲ 48.8% | -1.69▼ 189.4% | 0.28▲ 116.6% | -1.02▼ 464.3% | -5.64▼ 452.9% | -3.83▲ 32.1% | -0.76▲ 80.2% | -0.82▲ 0% |
EPS Growth % | -1.86% | -39.81% | 48.82% | -189.42% | 116.57% | -464.29% | -452.94% | 32.09% | 80.16% | 79.62% |
EPS (Basic) | 2.18 | 1.30 | 1.93 | -1.69 | 0.29 | -1.02 | -5.64 | -3.83 | -0.76 | - |
Diluted Shares Outstanding | 15.07M | 14.69M | 14.37M | 14.22M | 14.63M | 14.56M | 14.66M | 14.72M | 14.34M | 13.53M |
Basic Shares Outstanding | 14.57M | 14.44M | 14.12M | 14.22M | 14.4M | 14.56M | 14.66M | 14.72M | 14.34M | 13.53M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
ANIK Balance Sheet
Anika Therapeutics, Inc. (ANIK) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 206.33M | 202.94M | 234.31M | 177.38M | 168.53M | 169.55M | 163.31M | 113.65M | 103.36M | 93.56M |
Cash & Short-Term Investments | 157.26M | 159.01M | 184.94M | 98.32M | 94.39M | 86.33M | 68.74M | 55.63M | 57.48M | 41.02M |
Cash Only | 133.26M | 89.04M | 157.46M | 95.82M | 94.39M | 86.33M | 68.74M | 55.63M | 57.48M | 41.02M |
Short-Term Investments | 24M | 69.97M | 27.48M | 2.5M | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 23.82M | 20.77M | 23.08M | 24.1M | 29.84M | 34.63M | 26.36M | 23.59M | 23.69M | 25.77M |
Days Sales Outstanding | 76.67 | 71.84 | 73.5 | 67.43 | 73.7 | 111.04 | 79.65 | 71.82 | 76.64 | 75.03 |
Inventory | 22.04M | 21.3M | 22M | 46.21M | 36.01M | 39.77M | 24.43M | 23.81M | 18.79M | 22.84M |
Days Inventory Outstanding | 293.92 | 248.55 | 279.27 | 274.56 | 202.67 | 357.43 | 233.04 | 197.92 | 139.91 | 141.84 |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 43.78M | 10.62M | 3.4M | 3.94M |
Total Non-Current Assets | 76.29M | 76.05M | 96.4M | 188.22M | 179.01M | 179.58M | 107.32M | 89.09M | 86.91M | 85.83M |
Property, Plant & Equipment | 56.18M | 54.11M | 73.65M | 73.23M | 68.56M | 78.97M | 65M | 64.68M | 66.26M | 65.15M |
Fixed Asset Turnover | 2.02x | 1.95x | 1.56x | 1.78x | 2.16x | 1.44x | 1.86x | 1.85x | 1.70x | 1.77x |
Goodwill | 8.22M | 7.85M | 7.69M | 8.41M | 7.78M | 7.34M | 7.57M | 7.13M | 8.05M | 7.89M |
Intangible Assets | 10.63M | 9.19M | 7.58M | 91.16M | 82.38M | 74.6M | 2.58M | 2.49M | 1.65M | 1.65M |
Long-Term Investments | -4.77M | -7.21M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 12.16M |
Other Non-Current Assets | 1.25M | 4.9M | 7.48M | 15.42M | 20.29M | 17.22M | 30.69M | 13.62M | 9.67M | 4.3M |
Total Assets | 282.62M▲ 0% | 278.99M▼ 1.3% | 330.71M▲ 18.5% | 365.61M▲ 10.6% | 347.54M▼ 4.9% | 349.13M▲ 0.5% | 270.63M▼ 22.5% | 202.74M▼ 25.1% | 190.27M▼ 6.2% | 179.39M▲ 0% |
Asset Turnover | 0.40x | 0.38x | 0.35x | 0.36x | 0.43x | 0.33x | 0.45x | 0.59x | 0.59x | 0.62x |
Asset Growth % | 17.64% | -1.28% | 18.54% | 10.55% | -4.94% | 0.46% | -22.48% | -25.09% | -6.15% | -58.72% |
Total Current Liabilities | 13.07M | 11.29M | 16.28M | 36.87M | 29.8M | 27.91M | 31.06M | 23.31M | 21.91M | 20.97M |
Accounts Payable | 6.75M | 3.14M | 3.83M | 8.98M | 7.63M | 9.07M | 6.19M | 5.62M | 6.04M | 6.34M |
Days Payables Outstanding | 90 | 36.67 | 48.65 | 53.38 | 42.96 | 81.56 | 59.09 | 46.69 | 44.99 | 41.48 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1.94M |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 229K |
Other Current Liabilities | 3.43M | 3.7M | 5.83M | 20.43M | 13.84M | 11.3M | 18.73M | 12.16M | 15.87M | 2.75M |
Current Ratio | 15.78x | 17.98x | 14.39x | 4.81x | 5.66x | 6.07x | 5.26x | 4.88x | 4.72x | 4.46x |
Quick Ratio | 14.10x | 16.09x | 13.04x | 3.56x | 4.45x | 4.65x | 4.47x | 3.85x | 3.86x | 3.37x |
Cash Conversion Cycle | 280.59 | 283.71 | 304.12 | 288.61 | 233.42 | 386.9 | 253.6 | 223.04 | 171.56 | 175.4 |
Total Non-Current Liabilities | 6.05M | 4.09M | 26.05M | 56.34M | 30.66M | 35.65M | 27.31M | 25.45M | 24.9M | 24.52M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 24.2M | 0 |
Capital Lease Obligations | 0 | 0 | 21.37M | 20.88M | 19.24M | 28.82M | 25.91M | 24.01M | 0 | 69.75M |
Deferred Tax Liabilities | 5.39M | 3.54M | 4.33M | 11.89M | 10.16M | 6.44M | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 660K | 550K | 357K | 23.56M | 1.26M | 398K | 1.39M | 1.43M | 701K | 726K |
Total Liabilities | 19.13M | 15.38M | 42.33M | 93.2M | 60.45M | 63.56M | 58.37M | 48.75M | 46.8M | 45.49M |
Total Debt | 0 | 0 | 22.51M | 22.46M | 20.95M | 30.89M | 27.74M | 25.93M | 24.2M | 25.74M |
Net Debt | -133.26M | -89.04M | -134.96M | -73.35M | -73.43M | -55.44M | -41M | -29.7M | -33.28M | -15.28M |
Debt / Equity | - | - | 0.08x | 0.08x | 0.07x | 0.11x | 0.13x | 0.17x | 0.17x | 0.19x |
Debt / EBITDA | - | - | 0.56x | - | 1.24x | 1.70x | 1.84x | 8.59x | - | -3.88x |
Net Debt / EBITDA | -2.66x | -3.22x | -3.35x | - | -4.34x | -3.05x | -2.72x | -9.83x | - | 2.31x |
Interest Coverage | - | - | - | -18.09x | - | - | - | - | - | - |
Total Equity | 263.49M▲ 0% | 263.61M▲ 0.0% | 288.38M▲ 9.4% | 272.4M▼ 5.5% | 287.08M▲ 5.4% | 285.56M▼ 0.5% | 212.26M▼ 25.7% | 153.99M▼ 27.5% | 143.47M▼ 6.8% | 133.9M▲ 0% |
Equity Growth % | 18.28% | 0.05% | 9.39% | -5.54% | 5.39% | -0.53% | -25.67% | -27.45% | -6.83% | -64.78% |
Book Value per Share | 17.49 | 17.95 | 20.06 | 19.15 | 19.62 | 19.61 | 14.48 | 10.46 | 10.01 | 9.90 |
Total Shareholders' Equity | 263.49M | 263.61M | 288.38M | 272.4M | 287.08M | 285.56M | 212.26M | 153.99M | 143.47M | 133.9M |
Common Stock | 147K | 142K | 143K | 143K | 144K | 146K | 147K | 144K | 139K | 133K |
Retained Earnings | 199.51M | 218.23M | 245.43M | 221.44M | 225.58M | 210.72M | 128.05M | 71.67M | 60.79M | 55.73M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -4.78M | -5.53M | -5.9M | -4.54M | -5.72M | -6.44M | -5.94M | -6.78M | -4.96M | -5.31M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ANIK Cash Flow Statement
Anika Therapeutics, Inc. (ANIK) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 40.81M | 34.92M | 37.01M | 13.06M | 8.4M | 4.41M | -1.79M | 5.4M | 11.19M | 6.47M |
Operating CF Margin % | 35.98% | 33.08% | 32.29% | 10.01% | 5.68% | 3.87% | -1.48% | 4.51% | 9.92% | - |
Operating CF Growth % | 71.47% | -14.44% | 5.98% | -64.69% | -35.73% | -47.49% | -140.55% | 402.18% | 107.07% | -3315.3% |
Net Income | 31.82M | 18.72M | 27.19M | -23.98M | 4.13M | -14.86M | -82.67M | -56.38M | -10.88M | -11.06M |
Depreciation & Amortization | 4.29M | 5.91M | 5.99M | 14.99M | 14.32M | 14.49M | 14.22M | 8.12M | 5.73M | 5.54M |
Stock-Based Compensation | 5.81M | 11.05M | 6.09M | 0 | 11.09M | 14.31M | 15.24M | 13.13M | 10.08M | 13.86M |
Deferred Taxes | -1.2M | -1.82M | 794K | -3.54M | -1.77M | -5.27M | -6.33M | 260K | -7K | 83K |
Other Non-Cash Items | 2.45M | 4.26M | 3.58M | 39.05M | -4.66M | 7.56M | 69.87M | 53.37M | 7.08M | 7.79M |
Working Capital Changes | -2.36M | -3.2M | -6.64M | -13.46M | -14.72M | -11.82M | -12.12M | -13.09M | -823K | -9.74M |
Change in Receivables | 2.67M | 2.91M | -1.84M | 5.86M | -6.22M | -5.63M | -1.3M | 3.37M | 408K | -4.81M |
Change in Inventory | -6.52M | -7.58M | -5.58M | -14.18M | -6.62M | -6.87M | -11.4M | -9.42M | 30K | -5.9M |
Change in Payables | 3.89M | -1.67M | 767K | 822K | -1.1M | 1.97M | -11K | -2.51M | 42K | 740K |
Cash from Investing | -12.48M | -50.26M | 39.69M | -71.26M | -3.12M | -7.49M | -5.43M | -8.33M | -401K | -3.31M |
Capital Expenditures | -8.98M | -4.66M | -2.83M | -1.63M | -5.14M | -7.49M | -5.43M | -7.73M | -6.83M | -5.43M |
CapEx % of Revenue | 7.92% | 4.41% | 2.47% | 1.25% | 3.48% | 6.58% | 4.49% | 6.45% | 6.05% | 4.67% |
Acquisitions | 0 | 0 | -42.52M | -94.6M | -476K | 0 | 0 | 0 | 8.99M | 4.5M |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -3.5M | -45.6M | 42.52M | 0 | 0 | 0 | 0 | -600K | -2.57M | -2.38M |
Cash from Financing | 314K | -28.9M | -8.14M | -3.77M | -6.78M | -4.85M | -6.32M | -12.73M | -10.55M | -15.46M |
Debt Issued (Net) | 0 | 0 | 0 | -558K | -201K | -284K | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 0 | -30M | -30.29M | 1.52M | 0 | 0 | -5M | -10.91M | -8.98M | -13.7M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -30M | -30M | 0 | 0 | 0 | -5M | -10.91M | -9.48M | -14.2M |
Other Financing | 314K | 1.1M | 22.15M | -4.74M | -6.58M | -4.57M | -1.32M | -1.81M | -1.57M | -1.76M |
Net Change in Cash | 29M▲ 0% | -44.21M▼ 252.5% | 68.42M▲ 254.7% | -61.65M▼ 190.1% | -1.43M▲ 97.7% | -8.06M▼ 463.2% | -13.46M▼ 67.0% | -15.71M▼ 16.7% | 322K▲ 102.0% | -12.35M▲ 0% |
Free Cash Flow | 31.83M▲ 0% | 30.26M▼ 4.9% | 34.18M▲ 12.9% | 11.44M▼ 66.5% | 3.25M▼ 71.5% | -3.08M▼ 194.6% | -7.21M▼ 134.5% | -2.33M▲ 67.7% | 4.36M▲ 287.1% | 1.04M▲ 0% |
FCF Margin % | 28.07% | 28.67% | 29.82% | 8.77% | 2.2% | -2.7% | -5.97% | -1.94% | 3.87% | 0.89% |
FCF Growth % | 225.25% | -4.93% | 12.94% | -66.54% | -71.55% | -194.56% | -134.48% | 67.69% | 287.13% | 126.3% |
FCF per Share | 2.11 | 2.06 | 2.38 | 0.80 | 0.22 | -0.21 | -0.49 | -0.16 | 0.30 | 0.08 |
FCF Conversion (FCF/Net Income) | 1.28x | 1.87x | 1.36x | -0.54x | 2.03x | -0.30x | 0.02x | -0.10x | -1.03x | -0.09x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 15.09M | 5.56M | 9.26M | 0 | 1.23M | 106K | 3.12M | 3.99M | 0 | 0 |
ANIK Key Ratios
Anika Therapeutics, Inc. (ANIK) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 13.09% | 7.1% | 9.85% | -8.55% | 1.48% | -5.19% | -33.21% | -30.79% | -7.32% | -7.74% |
Return on Invested Capital (ROIC) | 27.58% | 10.7% | 15.66% | -12.05% | 0.95% | 1.24% | 0.32% | -2.59% | -7.07% | -7.96% |
Gross Margin | 75.87% | 70.37% | 74.92% | 52.91% | 56.12% | 64.33% | 68.33% | 63.38% | 56.56% | 58.59% |
Net Margin | 28.05% | 17.74% | 23.73% | -18.38% | 2.8% | -13.05% | -68.44% | -47.02% | -9.64% | -9.52% |
Debt / Equity | - | - | 0.08x | 0.08x | 0.07x | 0.11x | 0.13x | 0.17x | 0.17x | 0.19x |
Interest Coverage | - | - | - | -18.09x | - | - | - | - | - | - |
FCF Conversion | 1.28x | 1.87x | 1.36x | -0.54x | 2.03x | -0.30x | 0.02x | -0.10x | -1.03x | -0.09x |
Revenue Growth | 9.71% | -6.93% | 8.58% | 13.83% | 13.29% | -22.98% | 6.12% | -0.73% | -5.91% | 23.22% |
Related:ANIK Dividend History·ANIK Revenue History·ANIK Price History·ANIK P/E History·ANIK Financial Ratios·ANIK Institutional Holders
ANIK SEC Filings & Documents
Anika Therapeutics, Inc. (ANIK) SEC filings — annual & quarterly reports (10-K, 10-Q)
ANIK Frequently Asked Questions
Anika Therapeutics, Inc. (ANIK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Anika Therapeutics, Inc. (ANIK) reported $116.3M in revenue for fiscal year 2025. This represents a 9589% increase from $1.2M in 1996.
Anika Therapeutics, Inc. (ANIK) saw revenue decline by 5.9% over the past year.
Anika Therapeutics, Inc. (ANIK) reported a net loss of $11.1M for fiscal year 2025.
Dividend & Returns
Anika Therapeutics, Inc. (ANIK) has a return on equity (ROE) of -7.3%. Negative ROE indicates the company is unprofitable.
Anika Therapeutics, Inc. (ANIK) generated $1.0M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.